Epigenetics and Testicular Cancer: Bridging the Gap Between Fundamental Biology and Patient Care

Nicu, Alina-Teodora; Medar, Cosmin; Chifiriuc, Mariana Carmen; Pîrcălăbioru, Grațiela Grădișteanu; Burlibaşa, Liliana

doi:10.3389/fcell.2022.861995

Cited by 13 publications

(15 citation statements)

References 209 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, young age should represent an element in favor of good tolerance to treatment, regardless of any known side effects related to CAR-T cell therapy ( 95 ). Furthermore, a better understanding of the mechanisms of activation of the immune system, including epigenetic influence in immune checkpoint expression ( 108 ), could also lead to a reconsideration of therapy with immune checkpoint inhibitors against GCTs.…”

Section: Discussionmentioning

confidence: 99%

Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors

Schepisi

Gianni²,

Cursano³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Germ cell tumors (GCTs) represent a heterogeneous neoplasm family affecting gonads and rarely occurring in extragonadal areas. Most of patients have a good prognosis, often even in the presence of metastatic disease; however, in almost 15% of cases, tumor relapse and platinum resistance are the main challenges. Thus, novel treatment strategies with both improved antineoplastic activity and minor treatment-related adverse events compared with platinum are really expected. In this context, the development and the high activity demonstrated by immune checkpoint inhibitors in solid tumors and, subsequently, the interesting results obtained from the use of chimeric antigen receptor (CAR-) T cell therapy in hematological tumors, have stimulated research in this direction also in GCTs. In this article, we will analyze the molecular mechanisms underlying the immune action in the development of GCTs, and we will report the data from the studies that tested the new immunotherapeutic approaches in these neoplasms.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors

Schepisi

Gianni²,

Cursano³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Epigenetic modifications are increasingly recognised as important features of GCTs [33]. Hypermethylation and global remodelling of DNA methylation were reported to be key factors in mediating cisplatin resistance of testicular GCTs [34].…”

Section: Discussionmentioning

confidence: 99%

SIN3‐HDAC complex‐associated factor, a chromatin remodelling gene located in the 12p amplicon, is a potential germ cell tumour‐specific oncogene

Jhuang

Yang

Tseng

et al. 2022

The Journal of Pathology

View full text Add to dashboard Cite

A genetic hallmark of malignant germ cell tumours (GCTs) is isochromosome 12p, but oncogenes located in 12p that are specifically expressed in GCT have not yet been identified. SIN3-HDAC complex-associated factor (SINHCAF) is a subunit of the Sin3/histone deacetylase (HDAC) complex, and it defines a Sin3a-Hdac complex variant that is required for the self-renewal of mouse embryonic stem cells. This study demonstrated that SINHCAF is expressed in a vast majority of malignant GCTs and is rarely expressed in somatic malignancy. Fluorescence in situ hybridisation revealed SINHCAF amplification in malignant GCTs. SINHCAF silencing using shRNA reduced anchorage-dependent cell proliferation and tumoursphere formation and inhibited tumour cell migration and invasion in GCT cell lines. Moreover, in the GCT cell line NTERA2/D1, SINHCAF silencing inhibited the expression of genes associated with embryonic stem cells and induced the expression of genes associated with neuronal and white fat cell differentiation. Compared with somatic cell lines, GCT cell lines were more susceptible to HDAC inhibitor treatment. Thus, we identified SINHCAF to be a potential oncogene located in the amplicon of chromosome 12p and showed that SINHCAF was specifically expressed in malignant GCTs. HDAC inhibitor treatment may counteract the oncogenic activity of SINHCAF and is a promising therapeutic approach for GCTs.

show abstract

“…Similarly, KAT2B (PCAF) is overexpressed in TGCT and potentially promotes tumor progression by acetylating and activating the androgen receptor (AR). KAT6A and KAT9 are also overexpressed families in TGCT [96].…”

Section: Acetylation By Lysine Acetyltransferases (Kats)mentioning

confidence: 94%

“…In addition, SET1A is responsible for the mono-, di-, and trimethylation of histone H3 at lysine 4 (H3K4), which is associated with active transcription. Thus, SET1A could be a potential therapeutic target for testicular cancers [96].…”

Section: Methyltransferasesmentioning

confidence: 99%

Epigenetic Factors and ncRNAs in Testicular Cancer

Nuñez-Corona,

Contreras-Sanzón,

Puente-Rivera

et al. 2023

IJMS

View full text Add to dashboard Cite

Testicular cancer is the most prevalent tumor among males aged 15 to 35, resulting in a significant number of newly diagnosed cases and fatalities annually. Non-coding RNAs (ncRNAs) have emerged as key regulators in various cellular processes and pathologies, including testicular cancer. Their involvement in gene regulation, coding, decoding, and overall gene expression control suggests their potential as targets for alternative treatment approaches for this type of cancer. Furthermore, epigenetic modifications, such as histone modifications, DNA methylation, and the regulation by microRNA (miRNA), have been implicated in testicular tumor progression and treatment response. Epigenetics may also offer critical insights for prognostic evaluation and targeted therapies in patients with testicular germ cell tumors (TGCT). This comprehensive review aims to present the latest discoveries regarding the involvement of some proteins and ncRNAs, mainly miRNAs and lncRNA, in the epigenetic aspect of testicular cancer, emphasizing their relevance in pathogenesis and their potential, given the fact that their specific expression holds promise for prognostic evaluation and targeted therapies.

show abstract

Epigenetics and Testicular Cancer: Bridging the Gap Between Fundamental Biology and Patient Care

Cited by 13 publications

References 209 publications

Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors

Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors

SIN3‐HDAC complex‐associated factor, a chromatin remodelling gene located in the 12p amplicon, is a potential germ cell tumour‐specific oncogene

Epigenetic Factors and ncRNAs in Testicular Cancer

Contact Info

Product

Resources

About